Werlinich Asset Management LLC Makes New $1.06 Million Investment in Novo Nordisk A/S (NYSE:NVO)

Werlinich Asset Management LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 12,305 shares of the company's stock, valued at approximately $1,055,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. International Assets Investment Management LLC increased its stake in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock worth $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock worth $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $98,765,000. Marshall Wace LLP lifted its position in shares of Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company's stock valued at $98,696,000 after acquiring an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $42,017,000. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NVO. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $140.20.

Novo Nordisk A/S Stock Down 5.2 %

NYSE:NVO traded down $4.33 during mid-day trading on Friday, reaching $78.74. The stock had a trading volume of 21,239,835 shares, compared to its average volume of 9,296,463. The stock has a market cap of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. The business's 50 day moving average is $98.33 and its 200 day moving average is $117.69. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.